<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6563376\results\search\drugs\results.xml">
  <result pre="antiviral treatment is associated with the greatest clinical benefit, standard-dose" exact="oseltamivir" post="(75 mg twice daily in adults) for enteric administration is"/>
  <result pre="while awaiting results of influenza diagnostic tests. • Enterically administered" exact="oseltamivir" post="is recommended for influenza patients except for those with"/>
  <result pre="intravenous peramivir); cap-dependent endonuclease inhibitor (baloxavir marboxil); and adamantanes (e.g.," exact="amantadine" post="and rimantadine) (Table 4). NAIs and baloxavir have activity"/>
  <result pre="healthy outpatients. Meta-analyses of randomized placebo-controlled clinical trials of early" exact="oseltamivir" post="treatment of influenza in pediatric and adult outpatients have"/>
  <result pre="(12 years or older) ≥80 kg Single dose of 80 mg *FDA-approved oral" exact="oseltamivir" post="treatment dose for infants 14 days and older and less"/>
  <result pre="twice daily. The American Academy of Pediatrics has recommended an" exact="oseltamivir" post="treatment dose of 3.5 mg/kg orally twice daily for infants"/>
  <result pre="conducted in hospitalized influenza patients to establish the efficacy of" exact="oseltamivir" post="or other NAIs. A number of observational studies have"/>
  <result pre="did not [72]. A cohort study of early versus late" exact="oseltamivir" post="treatment reported a significant reduction in mortality and median"/>
  <result pre="Greece [78]. One French study reported delays in initiation of" exact="oseltamivir" post="treatment prescribed to hospitalized influenza patients and suggested empiric"/>
  <result pre="prescribed to hospitalized influenza patients and suggested empiric administration of" exact="oseltamivir" post="treatment in the emergency department for patients being admitted"/>
  <result pre="inhibitors are limited in critically ill influenza patients. Enterically administered" exact="oseltamivir" post="is the preferred treatment for most hospitalized patients, given"/>
  <result pre="most hospitalized patients, given the lack of data for intravenous" exact="peramivir" post="in this population. The use of inhaled zanamivir is"/>
  <result pre="for intravenous peramivir in this population. The use of inhaled" exact="zanamivir" post="is not recommended in in critically ill patients due"/>
  <result pre="bronchospasm in patients with underlying lung disease. Studies indicate that" exact="oseltamivir" post="administered orally or via oro/naso-gastric tube is well absorbed"/>
  <result pre="ambulatory patients [80]. Similarly, several observational studies indicate that enteric" exact="oseltamivir" post="reaches comparable plasma concentrations to non-critically ill patients in"/>
  <result pre="dosing [80, 88–92]. Of note, studies also suggest that increased" exact="oseltamivir" post="dosing does not provide additional clinical benefit in obese"/>
  <result pre="[49, 98]. For patients who cannot tolerate or absorb enteric" exact="oseltamivir" post="due to gastric stasis, malabsorption, or other gastrointestinal processes,"/>
  <result pre="due to gastric stasis, malabsorption, or other gastrointestinal processes, intravenous" exact="peramivir" post="may be an alternative [99, 100]; however, studies have"/>
  <result pre="100]; however, studies have not identified an advantage for intravenous" exact="peramivir" post="in comparison with enteric oseltamivir [101]. Notably, a randomized"/>
  <result pre="identified an advantage for intravenous peramivir in comparison with enteric" exact="oseltamivir" post="[101]. Notably, a randomized trial conducted in three influenza"/>
  <result pre="in three influenza seasons found similar clinical outcomes between IV" exact="peramivir" post="and enteric oseltamivir in hospitalized adult influenza patients [102];"/>
  <result pre="seasons found similar clinical outcomes between IV peramivir and enteric" exact="oseltamivir" post="in hospitalized adult influenza patients [102]; a separate trial"/>
  <result pre="separate trial did not identify significant additional clinical benefit of" exact="peramivir" post="in combination with standard-of-care therapy (which often included an"/>
  <result pre="randomized controlled trial also found similar clinical benefit between enteric" exact="oseltamivir" post="and intravenous peramivir in hospitalized influenza patients [104]. In"/>
  <result pre="also found similar clinical benefit between enteric oseltamivir and intravenous" exact="peramivir" post="in hospitalized influenza patients [104]. In 2018, a novel"/>
  <result pre="showed similar clinical benefit to 5 days of twice-daily oral" exact="oseltamivir" post="[105]. However, because these studies were limited to patients"/>
  <result pre="tract at 24 h compared with those receiving placebo or oral" exact="oseltamivir" post="[105]. However, it is unknown whether this reduction in"/>
  <result pre="assess the efficacy and safety of baloxavir in combination with" exact="oseltamivir" post="versus oseltamivir monotherapy in hospitalized influenza patients is currently"/>
  <result pre="efficacy and safety of baloxavir in combination with oseltamivir versus" exact="oseltamivir" post="monotherapy in hospitalized influenza patients is currently enrolling participants"/>
  <result pre="triple-combination antiviral drug (TCAD) therapy, which combines amantadine, ribavirin, and" exact="oseltamivir" post="for treatment of influenza in critically ill and high-risk"/>
  <result pre="to date have not shown a benefit of TCAD over" exact="oseltamivir" post="monotherapy [125–127]. Several novel antiviral compounds are in various"/>
  <result pre="variety of other immunomodulatory agents for treatment of influenza, including" exact="celecoxib" post="[137], statins, etanercept, pioglitazone, azithromycin [138], and interferons [139]."/>
  <result pre="for treatment of influenza, including celecoxib [137], statins, etanercept, pioglitazone," exact="azithromycin" post="[138], and interferons [139]. Conclusions Influenza vaccination can reduce"/>
  <result pre="should be tested by molecular assay. Antiviral treatment with standard-dose" exact="oseltamivir" post="delivered orally or enterally by oro or naso-gastric tube"/>
  <result pre="Care201620133710.1186/s13054-016-1512-127770828 55.Katzen J, Kohn R, Houk JL, Ison MG. Early" exact="oseltamivir" post="after hospital admission is associated with shortened hospitalization: a"/>
  <result pre="admission is associated with shortened hospitalization: a five-year analysis of" exact="oseltamivir" post="timing and clinical outcomes. Clin Infect Dis. 2018. 10.1093/cid/ciy860."/>
  <result pre="a meta-analysis of randomised controlled trialsLancet201538599791729173710.1016/S0140-6736(14)62449-125640810 66.MaloshREMartinETHeikkinenTBrooksWAWhitleyRJMontoASEfficacy and safety of" exact="oseltamivir" post="in children: systematic review and individual patient data meta-analysis"/>
  <result pre="randomized controlled trialsClin Infect Dis201866101492150010.1093/cid/cix104029186364 67.HibaVChowersMLevi-VinogradIRubinovitchBLeiboviciLPaulMBenefit of early treatment with" exact="oseltamivir" post="in hospitalized patients with documented 2009 influenza A (H1N1):"/>
  <result pre="influenza cases over six seasonsEpidemiol Infect2018146779980810.1017/S095026881800066329606178 74.RodriguezADiazEMartin-LoechesIet al.Impact of early" exact="oseltamivir" post="treatment on outcome in critically ill patients with 2009"/>
  <result pre="E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early" exact="oseltamivir" post="treatment on mortality in critically ill patients with different"/>
  <result pre="of print]. 79.MartinotMGronnwaldAGerberVet al.Analysis of delays in the prescription of" exact="oseltamivir" post="in hospitals and potential for improvementMed Mal Infect2019491596210.1016/j.medmal.2018.10.00830446349 80.ArianoRESitarDSZelenitskySAet"/>
  <result pre="for improvementMed Mal Infect2019491596210.1016/j.medmal.2018.10.00830446349 80.ArianoRESitarDSZelenitskySAet al.Enteric absorption and pharmacokinetics of" exact="oseltamivir" post="in critically ill patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet"/>
  <result pre="critically ill patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet al.Pharmacokinetics of" exact="oseltamivir" post="and oseltamivir carboxylate in critically ill patients receiving continuous"/>
  <result pre="patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet al.Pharmacokinetics of oseltamivir and" exact="oseltamivir" post="carboxylate in critically ill patients receiving continuous venovenous hemodialysis"/>
  <result pre="continuous venovenous hemodialysis and/or extracorporeal membrane oxygenationPharmacotherapy201232121061106910.1002/phar.115123208833 82.EylerRFKleinKCMuellerBAThe pharmacokinetics of" exact="oseltamivir" post="and oseltamivir carboxylate in a critically ill pediatric patient"/>
  <result pre="hemodialysis and/or extracorporeal membrane oxygenationPharmacotherapy201232121061106910.1002/phar.115123208833 82.EylerRFKleinKCMuellerBAThe pharmacokinetics of oseltamivir and" exact="oseltamivir" post="carboxylate in a critically ill pediatric patient receiving extracorporeal"/>
  <result pre="hemodialysisJ Pediatr Pharmacol Ther201217217317623118670 83.GiraudCManceauSOualhaMet al.High levels and safety of" exact="oseltamivir" post="carboxylate plasma concentrations after nasogastric administration in critically ill"/>
  <result pre="intensive care unitAntimicrob Agents Chemother201155143343510.1128/AAC.00813-1020937783 84.KromdijkWSikmaMAvan den BroekMPBeijnenJHHuitemaADde LangeDWPharmacokinetics of" exact="oseltamivir" post="carboxylate in critically ill patients: each patient is uniqueIntensive"/>
  <result pre="membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of" exact="oseltamivir" post="carboxylate in critically ill patients with pandemic (H1N1) influenzaTher"/>
  <result pre="Clin Pharm Ther201742666167110.1111/jcpt.1263628948652 88.LeeNHuiDSZuoZet al.A prospective intervention study on higher-dose" exact="oseltamivir" post="treatment in adults hospitalized with influenza a and B"/>
  <result pre="B infectionsClin Infect Dis201357111511151910.1093/cid/cit59724046309 89.NoelZRBastinMLTMontgomeryAAFlanneryAHComparison of high-dose versus standard dose" exact="oseltamivir" post="in critically ill patients with influenzaJ Intensive Care Med2017321057457710.1177/088506661663864926992784"/>
  <result pre="East Asia Infectious Disease Clinical Research NEffect of double dose" exact="oseltamivir" post="on clinical and virological outcomes in children and adults"/>
  <result pre="trialBMJ2013346f303910.1136/bmj.f303923723457 92.DixitRKhandakerGHayPet al.A randomized study of standard versus double dose" exact="oseltamivir" post="for treating influenza in the communityAntivir Ther201520768969810.3851/IMP280724912485 93.PaiMPLodiseTPJrOseltamivir and"/>
  <result pre="oseltamivir for treating influenza in the communityAntivir Ther201520768969810.3851/IMP280724912485 93.PaiMPLodiseTPJrOseltamivir and" exact="oseltamivir" post="carboxylate pharmacokinetics in obese adults: dose modification for weight"/>
  <result pre="influenza: a clinical perspectiveCurr Opin Infect Dis201831652052630299356 99.WhitleyRLaughlinACarsonSet al.Single dose" exact="peramivir" post="for the treatment of acute seasonal influenza: integrated analysis"/>
  <result pre="efficacy and safety from two placebo-controlled trialsAntivir Ther201520770971910.3851/IMP287425318121 100.IsonMGFraizJHellerBet al.Intravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsAntivir Ther201419434936110.3851/IMP268023985625 101.LeeJParkJHJwaHKimYHComparison"/>
  <result pre="and meta-analysisYonsei Med J201758477878510.3349/ymj.2017.58.4.77828540991 102.IsonMGHuiDSClezyKet al.A clinical trial of intravenous" exact="peramivir" post="compared with oral oseltamivir for the treatment of seasonal"/>
  <result pre="102.IsonMGHuiDSClezyKet al.A clinical trial of intravenous peramivir compared with oral" exact="oseltamivir" post="for the treatment of seasonal influenza in hospitalized adultsAntivir"/>
  <result pre="influenza in hospitalized adultsAntivir Ther201318565166110.3851/IMP244223111657 103.de JongMDIsonMGMontoASet al.Evaluation of intravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsClin Infect Dis20145912e172e18510.1093/cid/ciu63225115871"/>
  <result pre="hospitalized patientsClin Infect Dis20145912e172e18510.1093/cid/ciu63225115871 104.NakamuraSMiyazakiTIzumikawaKet al.Efficacy and safety of intravenous" exact="peramivir" post="compared with oseltamivir in high-risk patients infected with influenza"/>
  <result pre="Dis20145912e172e18510.1093/cid/ciu63225115871 104.NakamuraSMiyazakiTIzumikawaKet al.Efficacy and safety of intravenous peramivir compared with" exact="oseltamivir" post="in high-risk patients infected with influenza A and B"/>
  <result pre="A (H7N9) viral pneumoniaCrit Care Med2016446e318e32810.1097/CCM.000000000000161626934144 125.BeigelJHBaoYBeelerJet al.Oseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
  <result pre="Med2016446e318e32810.1097/CCM.000000000000161626934144 125.BeigelJHBaoYBeelerJet al.Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus" exact="oseltamivir" post="monotherapy for the treatment of influenza: a multicentre, double-blind,"/>
  <result pre="phase 2 trialLancet Infect Dis201717121255126510.1016/S1473-3099(17)30476-028958678 126.SeoSEnglundJANguyenJTet al.Combination therapy with amantadine," exact="oseltamivir" post="and ribavirin for influenza A infection: safety and pharmacokineticsAntivir"/>
  <result pre="trialLancet Infect Dis201717121255126510.1016/S1473-3099(17)30476-028958678 126.SeoSEnglundJANguyenJTet al.Combination therapy with amantadine, oseltamivir and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther201318337738610.3851/IMP247523264438 127.KimWYYoung"/>
  <result pre="of Medicine, 2018. 131.GenentechIA study of MHAA4549A in combination with" exact="oseltamivir" post="versus oseltamivir in participants with severe influenza a infection."/>
  <result pre="2018. 131.GenentechIA study of MHAA4549A in combination with oseltamivir versus" exact="oseltamivir" post="in participants with severe influenza a infection. ClinicalTrialsgov [internet]."/>
 </snippets>
</snippetsTree>
